{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:03:09Z","timestamp":1779915789294,"version":"3.53.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.clml.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T21:09:51Z","timestamp":1455916191000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7385","authenticated-orcid":false,"given":"Usama","family":"Gergis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Kuriakose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi Kathy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.004_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib2","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.004_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.004_bib6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bmt.2011.91","article-title":"The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries","volume":"47","author":"Abelsson","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.004_bib9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2009.10","article-title":"A\u00a0retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis","volume":"44","author":"Gupta","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib11","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib13","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib16","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbmt.2014.06.011","article-title":"Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis","volume":"20","author":"Robin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib18","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.004_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM200008313430913","article-title":"Myelofibrosis with myeloid metaplasia","volume":"343","author":"Guardiola","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.004_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.bbmt.2011.05.003","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk","volume":"18","author":"Nivison-Smith","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2016.02.004_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.02.004_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","article-title":"Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis","volume":"150","author":"Robin","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.004_bib23","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2010.026708","article-title":"Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:41Z","timestamp":1761870461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S2152265016000598"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}